StreetInsider.com News Articles

Oppenheimer Starts Connect Biopharma Holdings Ltd (CNTB) at Outperform

Thu, 09 Jul 2026 07:47:15 -0400

(Updated - July 9, 2026 7:47 AM EDT)

Oppenheimer initiates coverage on Connect Biopharma Holdings Ltd (NASDAQ: CNTB) with a Outperform rating and a price target of $8.00.

The analyst comments "We are initiating coverage of Connect Biopharma (CNTB) with an Outperform rating and an $8 PT. Connect is developing rademikibart for inflammatory respiratory diseases. A single-asset story, CNTB is built on rademikibart (formerly CBP-201), a next-generation human IgG4 anti-IL-4Rα antibody that binds with higher affinity than dupilumab and, uniquely in the class, drives receptor-independent bronchodilation via pHSP20, producing FEV1 gains within 15 minutes through IV formulation. That speed could allow rademikibart

Oppenheimer Starts Connect Biopharma Holdings Ltd (CNTB) at Outperform

Thu, 09 Jul 2026 07:47:15 -0400

(Updated - July 9, 2026 7:47 AM EDT)

Oppenheimer initiates coverage on Connect Biopharma Holdings Ltd (NASDAQ: CNTB) with a Outperform rating and a price target of $8.00.

Form 4 Connect Biopharma Holdin For: Jun 30 Filed by: Xanthopoulos Kleanthis Gabriel

Wed, 01 Jul 2026 16:27:00 -0400

si-local-file:///var/storage/secattach/20260701/26721122.html

Form 4 Connect Biopharma Holdin For: Jun 30 Filed by: Xanthopoulos Kleanthis Gabriel

Wed, 01 Jul 2026 16:27:00 -0400

si-local-file:///var/storage/secattach/20260701/26721122.html

Form 4 Connect Biopharma Holdin For: Jun 30 Filed by: LIU JEAN I

Wed, 01 Jul 2026 16:26:00 -0400

si-local-file:///var/storage/secattach/20260701/26721110.html

Form 4 Connect Biopharma Holdin For: Jun 30 Filed by: LIU JEAN I

Wed, 01 Jul 2026 16:26:00 -0400

si-local-file:///var/storage/secattach/20260701/26721110.html

Piper Sandler Starts Connect Biopharma Holdings Ltd (CNTB) at Overweight

Fri, 26 Jun 2026 03:50:39 -0400

Piper Sandler analyst Biren Amin initiates coverage on Connect Biopharma Holdings Ltd (NASDAQ: CNTB) with a Overweight rating and a price target of $7.00.

The analyst comments: “We are initiating coverage of Connect Biopharma (CNTB) with an Overweight rating and a $7 PT, based on rademikibart's differentiated mechanism, its potentially unique position as the only biologic in development for acute asthma and COPD exacerbations, and a near-term catalyst-rich setup anchored by Sept 2026 Seabreeze STAT topline data in asthma, followed shortly thereafter by the COPD readout. We believe CNTB is positioned to establish a first-mover advantage in the acute respiratory biologic

Piper Sandler Starts Connect Biopharma Holdings Ltd (CNTB) at Overweight

Fri, 26 Jun 2026 03:50:39 -0400

Piper Sandler analyst Biren Amin initiates coverage on Connect Biopharma Holdings Ltd (NASDAQ: CNTB) with a Overweight rating and a price target of $7.00.

H.C. Wainwright Reiterates Buy Rating on Connect Biopharma Holdings Ltd (CNTB)

Thu, 25 Jun 2026 06:49:49 -0400

H.C. Wainwright analyst Brandon Folkes reiterated a Buy rating and $7.00 price target on Connect Biopharma Holdings Ltd (NASDAQ: CNTB).

The analyst commented: "We view the AbbVie / Apogee transaction as a meaningful reminder that rademikibart’s strategic value may extend beyond the indication currently reflected in CNTB shares. CNTB remains primarily a Seabreeze acute asthma/COPD story, and we continue to believe that is the right near-term focus given the upcoming readouts and the differentiated acute exacerbation opportunity. However, the chronic respiratory opportunity and with rademikibart’s China AD data, Q4W treatment experience, and mechanistic differentiation within the IL-4Rα class make the asset

H.C. Wainwright Reiterates Buy Rating on Connect Biopharma Holdings Ltd (CNTB)

Thu, 18 Jun 2026 06:49:10 -0400

H.C. Wainwright analyst Brandon Folkes reiterated a Buy rating and $7.00 price target on Connect Biopharma Holdings Ltd (NASDAQ: CNTB).

The analyst commented: "The company also noted that enrollment in the Phase 2 Seabreeze STAT COPD study remains on track to complete this month, with COPD data expected soon after the asthma readout. We view the update as incrementally positive because it removes the remaining timing uncertainty around the most important near-term catalyst for CNTB. With Seabreeze Asthma now fully enrolled, COPD nearing completion, prior DMC review supporting continuation without a sample size increase, and cash runway into 2H27, we continue

Connect Biopharma completes enrollment in Phase 2 asthma drug study

Wed, 17 Jun 2026 09:00:24 -0400

Connect Biopharma Holdings Limited (Nasdaq: CNTB) announced the completion of enrollment in its Phase 2 Seabreeze STAT Asthma study, which is evaluating rademikibart as an adjunct to standard of care for acute exacerbations in patients with asthma and type 2 inflammation.

The study enrolled 160 participants globally who experienced an acute asthma exacerbation with an eosinophil count of at least 300 cells/μL. Participants received either a single dose of rademikibart or placebo, administered subcutaneously. The primary endpoint is treatment failure rate over 28 days following an acute exacerbation, with a key secondary endpoint measuring lung function at Week 1.

The company expects

Connect Biopharma Announces Completion of Enrollment of Phase 2 Seabreeze STAT Asthma Study Evaluating Rademikibart for the Treatment of Acute Exacerbations in Asthma

Wed, 17 Jun 2026 09:00:00 -0400

– On track to also complete enrollment in the Seabreeze STAT COPD study this month –

– Expect to report topline data from Seabreeze STAT Asthma study in early September 2026 –

– Strong balance sheet with cash runway into 2H 2027 –

SAN DIEGO, June 17, 2026 (GLOBE NEWSWIRE) -- Connect Biopharma Holdings Limited (Nasdaq: CNTB) (Connect Biopharma, Connect or the Company), a clinical-stage biopharmaceutical company focused on transforming care for the treatment of inflammatory diseases, today announced the completion of enrollment in its Phase 2 Seabreeze STAT Asthma

Connect Biopharma Announces Completion of Enrollment of Phase 2 Seabreeze STAT Asthma Study Evaluating Rademikibart for the Treatment of Acute Exacerbations in Asthma

Wed, 17 Jun 2026 09:00:00 -0400

– On track to also complete enrollment in the Seabreeze STAT COPD study this month –

– Expect to report topline data from Seabreeze STAT Asthma study in early September 2026 –

– Strong balance sheet with cash runway into 2H 2027 –

Form 4 Connect Biopharma Holdin For: May 29 Filed by: Huang James

Tue, 02 Jun 2026 16:31:00 -0400

si-local-file:///var/storage/secattach/20260602/26592239.html

Form 4 Connect Biopharma Holdin For: May 29 Filed by: Huang James

Tue, 02 Jun 2026 16:31:00 -0400

si-local-file:///var/storage/secattach/20260602/26592239.html

Form EFFECT Connect Biopharma Holdin

Tue, 02 Jun 2026 06:09:00 -0400

si-local-file:///var/storage/secattach/20260602/26586861.html

Form EFFECT Connect Biopharma Holdin

Tue, 02 Jun 2026 06:09:00 -0400

si-local-file:///var/storage/secattach/20260602/26586861.html

Canaccord Starts Connect Biopharma Holdings Ltd (CNTB) at Buy

Tue, 26 May 2026 05:06:49 -0400

Canaccord analyst Edward Nash initiates coverage on Connect Biopharma Holdings Ltd (NASDAQ: CNTB) with a Buy rating and a price target of $6.00.

For an analyst ratings summary and ratings history on Connect Biopharma Holdings Ltd click here. For more ratings news on Connect Biopharma Holdings Ltd click here.

Shares of Connect Biopharma Holdings Ltd closed at $2.35 yesterday.

Cantor Fitzgerald Starts Connect Biopharma Holdings Ltd (CNTB) at Overweight

Thu, 21 May 2026 06:35:10 -0400

(Updated - May 21, 2026 6:35 AM EDT)

Cantor Fitzgerald analyst Olivia Brayer Saunders initiates coverage on Connect Biopharma Holdings Ltd (NASDAQ: CNTB) with a Overweight rating and a price target of $4.00.

The analyst comments "We are initiating coverage of Connect Biopharma (CNTB) with an OW rating and a $4 PT ahead of the company's phase 2 SEABREEZE STAT readouts in acute asthma and acute COPD, expected in 3Q26. The setup is relatively straightforward on this one: it's an acute-care biologic story. ● CNTB is trying to answer a simple but important question: can an IL-4Rα biologic work fast enough to

Cantor Fitzgerald Starts Connect Biopharma Holdings Ltd (CNTB) at Overweight

Thu, 21 May 2026 06:35:10 -0400

(Updated - May 21, 2026 6:35 AM EDT)

Cantor Fitzgerald analyst Olivia Brayer Saunders initiates coverage on Connect Biopharma Holdings Ltd (NASDAQ: CNTB) with a Overweight rating and a price target of $4.00.

Form SCHEDULE 13G/A Connect Biopharma Holdin Filed by: Wei Zheng

Fri, 15 May 2026 13:48:00 -0400

si-local-file:///var/storage/secattach/20260515/26503463.html

Form SCHEDULE 13G/A Connect Biopharma Holdin Filed by: Wei Zheng

Fri, 15 May 2026 13:48:00 -0400

si-local-file:///var/storage/secattach/20260515/26503463.html

Form F-3 Connect Biopharma Holdin

Fri, 15 May 2026 08:32:00 -0400

si-local-file:///var/storage/secattach/20260515/26500146.html

Form F-3 Connect Biopharma Holdin

Fri, 15 May 2026 08:32:00 -0400

si-local-file:///var/storage/secattach/20260515/26500146.html

Connect Biopharma to Present at the H.C. Wainwright 4th Annual BioConnect Investor Conference

Tue, 12 May 2026 16:05:00 -0400

SAN DIEGO, May 12, 2026 (GLOBE NEWSWIRE) -- Connect Biopharma Holdings Limited (Nasdaq: CNTB) (Connect Biopharma, Connect or the Company), a clinical-stage biopharmaceutical company focused on transforming care for the treatment of inflammatory diseases, today announced that Company management will participate in a fireside chat at the H.C. Wainwright 4^th Annual BioConnect Investor Conference on Tuesday, May 19, 2026 at 9:30 a.m. ET.

The live webcast of the presentation may be accessed via the Investors section of the Connect website at investors.connectbiopharma.com. An archived replay of the event will be available on the website for